EUVIMEDEUVIMED entdecken
Vergleichsstudie

Cost-Effectiveness Analysis of Adding Ivabradine to Current Standard Therapy Versus Standard Therapy Alone in Patients with Chronic Heart Failure in Japan

Takayuki Inomata, Takeshi Fukuda, Nobuya Yamashita, Koji Niibe, Sven Demiya, Hiroyuki Matsuda, Ataru Igarashi

International Heart Journal · 2024

DOI: 10.1536/ihj.24-194 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Heart Journal, 2024. Verfasst von Takayuki Inomata und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences. Hauptthemen laut MEDLINE: Ivabradine, Heart Failure, Cost-Benefit Analysis, Quality-Adjusted Life Years. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IvabradineHeart FailureCost-Benefit AnalysisQuality-Adjusted Life YearsBenzazepinesCardiovascular AgentsHumansJapanMaleFemaleAgedChronic DiseaseMiddle AgedHeart RateMarkov ChainsStroke VolumeCost-Effectiveness Analysis

Stichwörter der Autor:innen

Economic evaluationHeart rateHospitalizationQuality-Adjusted Life Years

Substanzen

IvabradineBenzazepinesCardiovascular Agents

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences.
  • Policy Planning and Communications External Affairs, Corporate Planning Division, Ono Pharmaceutical Co. Ltd.
  • Data Strategy & Planning, Digital Strategy & Planning Department, Ono Pharmaceutical Co. Ltd.
  • Real World Evidence Solutions & HEOR, IQVIA Solutions Japan G.K.
  • Department of Public Health, Yokohama City University School of Medicine.
  • Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo.

Zitieren

APA

Inomata, T., Fukuda, T., Yamashita, N., Niibe, K., Demiya, S., Matsuda, H., & Igarashi, A. (2024). Cost-Effectiveness Analysis of Adding Ivabradine to Current Standard Therapy Versus Standard Therapy Alone in Patients with Chronic Heart Failure in Japan. International Heart Journal. https://doi.org/10.1536/ihj.24-194

Vancouver

Inomata T, Fukuda T, Yamashita N, Niibe K, Demiya S, Matsuda H, et al. Cost-Effectiveness Analysis of Adding Ivabradine to Current Standard Therapy Versus Standard Therapy Alone in Patients with Chronic Heart Failure in Japan. International Heart Journal. 2024. doi:10.1536/ihj.24-194

BibTeX
@article{Inomata2024,
  author = {Inomata, Takayuki and Fukuda, Takeshi and Yamashita, Nobuya and Niibe, Koji and Demiya, Sven and Matsuda, Hiroyuki and Igarashi, Ataru},
  title = {Cost-Effectiveness Analysis of Adding Ivabradine to Current Standard Therapy Versus Standard Therapy Alone in Patients with Chronic Heart Failure in Japan},
  journal = {International Heart Journal},
  year = {2024},
  doi = {10.1536/ihj.24-194}
}
Kostenlos starten →